Catridecacog, sold under the brand name Tretten in the US and NovoThirteen in the EU
[NH]
New Drugs Online Report for catridecacog
Page accessed July 2, 2015) is a class of
recombinant factor XIII
Factor XIII, or fibrin stabilizing factor, is a plasma protein and zymogen. It is activated by thrombin to factor XIIIa which crosslinks fibrin in coagulation. Deficiency of XIII worsens clot stability and increases bleeding tendency.
Huma ...
A-subunit based
biopharmaceutical
A biopharmaceutical, also known as a biological medical product, or biologic, is any pharmaceutical drug product manufactured in, extracted from, or semisynthesized from biological sources. Different from totally synthesized pharmaceuticals, t ...
medicine, indicated in patients with a rare clotting disorder, congenital factor XIII A-subunit deficiency, which is a kind of
Factor XIII deficiency. The medication prevents bleeding in patients with this condition, and has been approved by the U.S.
Food and Drug Administration
The United States Food and Drug Administration (FDA or US FDA) is a List of United States federal agencies, federal agency of the United States Department of Health and Human Services, Department of Health and Human Services. The FDA is respo ...
(FDA) for this use in the US in 2014.
Catridecacog: First drug to treat rare genetic blood clotting disorder
''The Pharmacist'' February 01, 2014 It was brought to market by Novo Nordisk
Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, with production facilities in nine countries and affiliates or offices in five. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S ...
.[
]
References
*
*
External links
*
Antihemorrhagics
Biopharmaceuticals
Orphan drugs
Drugs developed by Novo Nordisk
{{blood-drug-stub